COPD fact and figures


Chronic obstructive pulmonary disease(COPD) is the world's 4th leading cause of death.1

251 millions

251 milllion people live with COPD worldwide2

ambulance hosp admissions

COPD is a major cause of hospital admissions.3


The annual cost of COPD is estimated at €48.4 billion in Europe alone.4

man walking

COPD also affects patient's quality of life reducing their ability to stay active.5

Around the world


leading cause of death by 2030.6

COPD deaths expected to increase by 30% in the coming years.7

40 yrs

First symptoms appear at around 40 years.8


Higher mortality ratio among women.9


comorbidities per patient.10

Emerging studies demonstrate the benefits of home NIV

Recent evidence indicates that treatment with home non-invasive ventilation (NIV) has benefits for COPD patients with chronic stable hypercapnia.   

Home NIV solutions

 ResMed connected home NIV solutions can be used to effectively manage and monitor COPD patients at home 

Download the toolkit

The COPD toolkit offers clinical and practical information on the management of COPD with home NIV, as well as exclusive workshops, interviews and videos.  

As part of the registration process, ResMed will be collecting your personal information. We will use your personal information to verify that you are a healthcare professional. Your personal information will be collected in accordance with ResMed’s Privacy Policy. 
[contact-form-7 id="11414" title="Home NIV in COPD (landing)"]


* With Stellar, therapy data is updated once a day. With Lumis, data is available one hour after the end of each therapy session. 

    1. Global Initiative for Chronic Obstructive Lung Disease, Pocket Guide to COPD Diagnosis,Management and Prevention, 2018 report.  (accessed August 31, 2018). 
    2. World Health Organization.   (accessed January 31, 2019) .
  1. National Clinical Guideline Centre (UK). Chronic Obstructive Pulmonary Disease: Management of Chronic Obstructive Pulmonary Disease in Adults in Primary and Secondary Care. Royal College of Physicians (UK), 2010. (accessed August 31, 2018).
  2. European Lung White Book: the economic burden of lung disease. The European Lung Foundation (ELF) and the European Respiratory Society (ERS). (accessed August 31, 2018). 
  3. Margarethe E. Wacker et al., Assessing health-related quality of life in COPD: comparing generic and disease-specific instruments with focus on comorbidities. BMC Pulmonary Medicine, 2016, DOI 10.1186/s12890-016-0238-9 (accessed February 20, 2019). 
  4. WHO, Chronic obstructive pulmonary disease (COPD) (accessed August 31, 2018). 
  5. WHO, Burden of COPD.  (accessed August 31, 2018). 
  6. COPD | National Heart, Lung, and Blood Institute (NHLBI). #Risk-Factors. (Accessed: May 4, 2018). 
  7. Laviolette, Louis et al. “Chronic Obstructive Pulmonary Disease in Women.” Canadian Respiratory Journal: Journal of the Canadian Thoracic Society 14.2 (2007)  (accessed August 31, 2018). 
  8. Dal Negro RW et al., Prevalence of different comorbidities in COPD patients by gender and GOLD stage. doi:10.1186/s40248-015-0023-2. 
  9. Murphy P et al., Effect of Home Noninvasive Ventilation With Oxygen Therapy vs Oxygen Therapy Alone on Hospital Readmission or Death After an Acute COPD Exacerbation. A Randomized Clinical Trial, JAMA. Published online May 21, 2017. doi:10.1001/jama.2017.4451. 
  10. Murphy PB et al. Cost-Effectiveness of Home Oxygen Therapy-Home Mechanical Ventilation (HOT-HMV) for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) with Chronic Hypercapnic Respiratory Failure Following an Acute Exacerbation of COPD in the United Kingdom (UK). American Journal of Respiratory and Critical Care Medicine 2018;197:A2517. 
  11. Dreher M et al., Registry of Stable Hypercapnic Chronic Obstructive Pulmonary Disease Treated With Non-Invasive Ventilation – HOmeVent Registry. ATS, San Diego, 2018. Identifier: NCT02811588.